Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
Clinical trial NCT07432867 · RECRUITING
Trial details
- NCT number
- NCT07432867
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-25
- Primary completion
- 2032-02-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.